BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory condition. Given patients with COPD continue to experience exacerbations despite the availability of effective therapies, anti-inflammatory treatments targeting novel pathways are needed. Kinases, notably the phosphoinositide 3-kinases (PI3K), are thought to be involved in chronic airway inflammation, with this pathway proposed as a critical regulator of inflammation and oxidative stress response in COPD. CHF6523 is an inhaled PI3K
- Govoni, M.
- Bassi, M.
- Girardello, L.
- Lucci, G.
- Rony, F.
- Charretier, R.
- Galkin, D.
- Faietti, M. L.
- Pioselli, B.
- Modafferi, G.
- Benfeitas, R.
- Bonatti, M.
- Miglietta, D.
- Clark, J.
- Pedersen, F.
- Kirsten, A. M.
- Beeh, K. M.
- Kornmann, O.
- Korn, S.
- Ludwig-Sengpiel, A.
- Watz, H.
Keywords
- Humans
- *Pulmonary Disease, Chronic Obstructive/drug therapy/diagnosis
- Male
- Female
- Middle Aged
- *Cross-Over Studies
- Double-Blind Method
- Aged
- *Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors/metabolism
- Administration, Inhalation
- Phosphoinositide-3 Kinase Inhibitors/therapeutic use/pharmacology
- Treatment Outcome
- Gene expression profiling
- Multi-omics
- Phosphatidylinositol 3-kinases
- Proteomics
- Therapeutics
